Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNomura Holdings Inc
Latest Disclosed Ownership14,299 shares
Latest Disclosed Value $ 4,731,110
Nomura Holdings Inc ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Nomura Holdings Inc filed a 13F-HR form disclosing ownership of 14,299 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $4,085,224 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 22,437 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -36.27% during the quarter. The current value of the position is $3,724,890 USD.

Nomura Holdings Inc has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 15,500 of underlying shares valued at $5,128,485 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,299 -8,138 -36.27 4,731 -46.97 0.0096
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,437 20,711 1,199.94 8,922 1,033.67 0.0119
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,726 1,726 787 0.0012
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -17,849 -100.00 0 -100.00
2025-01-13 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 17,849 11,423 177.76 4,909 214.48 0.0113
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,849 11,423 4,909 0.0082
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,426 6,426 1,562 0.0030
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,572 -100.00 0 -100.00
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,572 -10,779 -87.27 299 -87.95 0.0008
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,351 12,351 2,474 0.0079
2023-02-15 2022-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -6,113 -100.00 0 -100.00
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -6,113 0
2022-11-15 2022-09-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 6,113 -11,330 -64.95 1,225 -52.56 0.0050
2022-08-17 2022-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS CMN 02043Q107 17,443 17,443 2,582 0.0089
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 17,443 17,443 2,582 0.0072
2022-05-17 2022-03-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -22,403 -100.00 0 -100.00
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 22,403 20,674 1,195.72 3,814 1,048.80 0.0097
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 1,729 -1,993 -53.55 332 -47.39 0.0008
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 3,722 -2,700 -42.04 631 0.0016
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 6,422 -12,800 -66.59 1 -100.00 0.0021
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 19,222 19,222 2 0.0042
2018-08-17 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -5,488 -100.00 0 -100.00
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 5,488 0 0.00 698 0.00 0.0006
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 5,488 5,488 698 0.0012
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -10,096 -100.00 0 -100.00
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 10,096 100 1.00 951 21.15 0.0027
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 9,996 -69,075 -87.36 785 -91.32 0.0028
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 79,071 79,071 0.00 9,046 0.0254
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 0 -2,690 -100.00 0 -100.00
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 2,690 2,687 89,566.67 206 0.0006
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 3 -3,506 -99.91 0 -100.00
2014-02-14 2013-12-31 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 3,509 -28,399 -89.00 225 -89.00 0.0010
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS CMN 02043Q107 31,908 31,908 2,046 0.0123
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 22,500 -36.62 8,947 -44.73 n/a n/a n/a
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 35,500 16,188 n/a n/a n/a
2025-08-18 2025-06-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 0 0 n/a n/a n/a
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM Call 9,000 2,430 n/a n/a n/a
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-01-13 2024-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Call 1,500 -82.95 413 -80.73 n/a n/a n/a
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 1,500 413 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Call 8,800 2,138 n/a n/a n/a
2024-03-27 2023-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-03-27 2023-12-31 13F/A ALNYLAM PHARMACEUTICALS COM Call 0 0 n/a n/a n/a
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM Call 0 0 n/a n/a n/a
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM Call 7,000 1,240 n/a n/a n/a
2022-11-15 2022-09-30 13F ALNYLAM PHARMACEUTICALS CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-08-17 2022-06-30 13F/A ALNYLAM PHARMACEUTICALS CMN Call 60,000 8,882 n/a n/a n/a
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS CMN Call 60,000 8,882 n/a n/a n/a
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS CMN Call 15,000 1,716 n/a n/a n/a
2015-02-17 2014-12-31 13F ALNYLAM PHARMACEUTICALS CMN Call 0 -100.00 0 -100.00 n/a n/a n/a
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS CMN Call 20,000 0.00 1,534 21.55 n/a n/a n/a
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS CMN Call 20,000 1,262 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM Put 15,500 -13.89 5,128 -28.35 n/a n/a n/a
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 18,000 -33.33 7,158 -41.87 n/a n/a n/a
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 27,000 12,312 n/a n/a n/a
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-01-13 2024-09-30 13F/A ALNYLAM PHARMACEUTICALS COM Put 1,500 -86.73 413 -84.99 n/a n/a n/a
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM Put 1,500 413 n/a n/a n/a
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM Put 11,300 2,746 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.